39results about How to "Simple crystallization process" patented technology

The invention discloses novel industrial crystallizing technology for cefuroxime sodium. Recrystallizing of cefuroxime sodium is realized by adopting a mode combining supercritical fluid extraction technology with conventional crystallizing technology. In a crystallizing system, the processes of extracting, adsorbing, crystallizing and drying are completed under specific temperature and pressure conditions and under joint action of supercritical fluid, solvent, an extraction pool and a crystallization pool to realize recrystallizing of cefuroxime sodium. The novel industrial crystallizing technology is high in separation efficiency and few in impurity, and quality of cefuroxime sodium is improved greatly.

The invention relates to a sodium acetate production technology. The sodium acetate production technology comprises the following steps: synthesizing, purifying, filtering, concentrating, crystallizing, centrifuging and spin-drying, checking, and packaging. A crystallizing device of the sodium acetate production technology is different from a current jacket-type indirect contact cooling device. Acold gas in a lower temperature is used to be fed into concentrated liquid for cooling, diffusion of the cold gas and the liquid is rapid, and contact is uniform, so cooling efficiency is better. Through installing multiple cold gas pipelines, a heater and an air pressure sensor, a problem of blocking and coagulating an air outlet can be rapidly detected and solved, so a crystallizing flow is simpler, and easy to automatically operate and control. An obtained sodium acetate trihydrate product is higher in purity, and reaches a detecting requirement.

The invention discloses a method for preparing crystalline form 6 of Sofosbuvir. The method comprises the following steps: 1) adding Sofosbuvir in a mixed solvent of an alcohols solvent and water, heating the material and dissolving the material; 2) cooling the solution obtained in the step 1) for crystallization; and 3) filtering the solid after crystallization and drying the solid to obtain crystalline form 6 of Sofosbuvir. Compared with the original preparation method of crystalline form 6, the crystallization technology of the present invention is used for preparing crystalline form 6 of Sofosbuvir, and the method has the advantages of high yield, loose product, easy drying, little application amount of the solvent, environmental protection and simple operation.

The invention provides 2,2-dimethoxy-1,2-di-[4-(meth)acryloyloxy]phenylethane-1-one represented by the following formula (A):(wherein R1 and R2, which may be identical to or different from each other, each represent a hydrogen atom or a methyl group).

The invention discloses a novel industrial crystallization technology for cefamandole nafate. Recrystallization of the cefamandole nafate is realized through combination of a supercritical fluid extraction technology and a traditional crystallization technology. In a whole crystallization system, extraction, adsorption, crystallization and drying processes are finished under the coaction of a supercritical fluid, a solvent, an extraction pool and a crystallization pool under specific temperature and pressure conditions, and recrystallization of the cefamandole nafate is realized. According to the method, the separation efficiency is high, the product purity is high, few impurities exist, and the preparation product quality is greatly improved.

The invention belongs to the technical field of medicament crystallization processes, and discloses a crystallization process for preparing high-crystallinity myo-inositol with a large particle size. A product prepared by the crystallization process is columnar crystalline myo-inositol, a particle size thereof can be more than 100 microns, the product is high in crystallinity and uniform in particle size distribution, and the shortcomings of low content, high moisture absorption and caking rate, long suction filtration and drying time, poor flowability and the like of powdery myo-inositol prepared by the prior art are overcome. The crystallization process has the characteristics of process simplicity, low equipment requirements and the like, production of a dihydrate crystal form H in a process is avoided, caking and crystal breaking in a drying process are avoided, suction filtration and drying time is shortened, and process cost is reduced.

The invention discloses an isavuconazole monohydrate crystal form and further discloses a preparation method thereof. The method comprises the following steps: by taking (2S,3R)-3-(2,5-difluoro)-3-hydroxyl-2-methyl-4-(1H-1,2,4-triazole-1-yl) butyronitrile, diethylphosphorodithioate and 2-bromo-4 cyan-acetophenone as raw materials, carrying out steps of an addition reaction and penta-heterocycle closing and a unique post-treatment and crystallization process to prepare isavuconazole monohydrate which is white crystalized solid powder. The solid powder has the crystal form when being detected by XRPD (X-ray Powder Diffraction). Compared with previous isavuconazole amorphous powder, isavuconazole monohydrate crystal powder prepared by the process has the advantages of simple crystallization process, high operability, good stability and the like, and industrialized production is easier to realize.

The invention relates to a method for separating out nafcillin acid crystal from a nafcillin sodium aqueous solution, which comprises the following steps: adding one of ethyl acetate, butyl acetate, n-butanol, n-hexane or petroleum ether as an extracting agent into the nafcillin sodium aqueous solution, and dripping an acidifying agent into the solution to make the pH value to be between 1.5 and 2.0 so as to separate out the crystal; and separating out the crystal, washing the crystal by purified water to make the pH value of washing liquor to be 4.0, drying the crystal at a temperature of between 45 and 55 DEG C to ensure that the moisture is below 3 percent to obtain the nafcillin acid crystal. The nafcillin acid crystal separated out by the extracting agent has the advantages of good crystal form, easy filtration, easy drying, less residual solvent in a product, and good quality; and the content of nafcillin acid is more than 93 percent. The crystallization method has the advantages of simple crystallize process, single extracting agent, and easy reclamation.

The invention discloses a novel industrial crystallizing technology for cefathiamidine, Recrystallization of the cefathiamidine is achieved by adopting the mode of combining the supercritical fluid extraction technology and the traditional crystallizing technology. In the whole crystallizing system, the process of extraction, adsorption, crystallization and drying is completed under the joint effect of supercritical fluid, a solvent, an extraction pool and a crystallizing pool under the condition of specific temperature and pressure, and recrystallization of the cefathiamidine is achieved. The method is high in separation efficiency and product purity and few in impurities, and greatly improves the quality of preparation products.

The invention discloses an azlocillin sodium crystal preparation and a preparation method thereof. The preparation method comprises the following steps: step 1, dissolving a crude azlocillin sodium product in a mixed solvent of methanol and ethyl methyl ketone, adding active carbon for adsorption, carrying out filtering, cooling the obtained filtrate to allow a crystal to be precipitated, washing the crystal with a mixed solution of methanol and ethyl methyl ketone and carrying out pressure-reduced drying so as to obtain a primary refined azlocillin sodium product; and step 2, dissolving the primary refined azlocillin sodium product in a hot ethyl methyl ketone solution, carrying out press filtration with a high-efficiency filter, subjecting obtained mixed liquor to cooling, pressure reduction and concentration, then carrying out cooling to allow a crystal to be precipitated and subjecting the precipitated crystal to filtering and pressure-reduced drying so as to obtain the azlocillin sodium crystal preparation. The azlocillin sodium crystal preparation provided by the invention has the advantages of a small particle size, uniform particle size distribution, good fluidity, simple crystallization process, low residual quantity of the organic solvent, high stability, good security, small toxic and side effects, low proneness to allergy, etc.

The invention provides a novel crystal form of an EGFR inhibitor, and a preparation method thereof, and belongs to the field of medicinal chemistry. The crystal form has the characteristics of good stability and low toxicity. The preparation method comprises the following steps: suspending and stirring the EGFR inhibitor and a solvent, filtering, drying, and placing the dried product in humid air to obtain the product. The preparation method is simple to operate, mild in condition, good in crystallinity and easy for industrial production.

The invention provides a crystallization process of polycrystalline silicon and an ingot casting process of polycrystalline silicon. The crystallization process comprises the following steps: when a silicon material is in the state of coexistence of solid silicon and liquid silicon, the temperature of the top of an ingot furnace is kept so as to continuously melt solid silicon, and the temperature of the top in the ingot furnace is gradually lowered to enable the liquid silicon to be subjected to recrystallization to form the polycrystalline silicon ingot. The crystallization treatment is performed to the liquid silicon, when the silicon material is in the state of mixing of solid and liquid, so the temperatures of liquid silicon in all the ingot furnaces are basically the same, latent heat of the liquid silicon is the same, and therefore the crystallization velocity of the liquid silicon is enabled to be stable, the crystallization stability of liquid silicon is improved, and the properties of solar cells manufactured by the polycrystalline silicon ingot is improved. Meanwhile, the crystallization process of the polycrystalline silicon has the characteristics of simple process and high production efficiency.

The invention belongs to the technical field of medicament crystallization processes, and discloses a crystallization process for preparing high-crystallinity myo-inositol with a large particle size. A product prepared by the crystallization process is columnar crystalline myo-inositol, a particle size thereof can be more than 100 microns, the product is high in crystallinity and uniform in particle size distribution, and the shortcomings of low content, high moisture absorption and caking rate, long suction filtration and drying time, poor flowability and the like of powdery myo-inositol prepared by the prior art are overcome. The crystallization process has the characteristics of process simplicity, low equipment requirements and the like, production of a dihydrate crystal form H in a process is avoided, caking and crystal breaking in a drying process are avoided, suction filtration and drying time is shortened, and process cost is reduced.

The invention provides a tildipirosin 1,4-dioxane solvate and a preparation method thereof. Characteristic peaks occur in an X-ray powder diffraction pattern represented by 2theta when 2theta is equal to 6.06+ / -0.2, 8.42+ / -0.2, 9.34+ / -0.2, 9.94+ / -0.2, 10.28+ / -0.2, 12.34+ / -0.2, 13.44+ / -0.2, 13.74+ / -0.2, 14.66+ / -0.2, 15.58+ / -0.2, 15.78+ / -0.2, 16.40+ / -0.2, 17.00+ / -0.2, 17.90+ / -0.2, 18.60+ / -0.2, 19.32+ / -0.2, 20.10+ / -0.2, 21.40+ / -0.2, 22.34+ / -0.2, 22.68+ / -0.2, 23.34+ / -0.2 and 24.18+ / -0.2. The preparation method employs a constant-temperature suspended crystal transformation process and is simple in process and low in energy consumption. The tildipirosin 1,4-dioxane solvate is in a rod shape and crystal is of a regular shape.

The invention discloses a novel crystallization method for preparing a sofosbuvir crystal form 6. Compared with an original preparation method of the crystal form 6, the novel crystallization method disclosed by the invention has the advantages that the purification effect is good, products are easy to dry, an environment-friendly effect is achieved and the like since sofosbuvir is prepared from a solution containing various organic mixed solvents through cooling crystallization.

The invention relates to a sodium acetate production technology. The sodium acetate production technology comprises the following steps: synthesizing, purifying, filtering, concentrating, crystallizing, centrifuging and spin-drying, checking, and packaging. A crystallizing device of the sodium acetate production technology is different from a current jacket-type indirect contact cooling device. Acold gas in a lower temperature is used to be fed into concentrated liquid for cooling, diffusion of the cold gas and the liquid is rapid, and contact is uniform, so cooling efficiency is better. Through installing multiple cold gas pipelines, a heater and an air pressure sensor, a problem of blocking and coagulating an air outlet can be rapidly detected and solved, so a crystallizing flow is simpler, and easy to automatically operate and control. An obtained sodium acetate trihydrate product is higher in purity, and reaches a detecting requirement.

The invention discloses a cefodizime sodium compound solid, a method for preparing the same and a pharmaceutical preparation of the cefodizime sodium compound solid, wherein the method for preparing the cefodizime sodium compound solid comprises the following steps of: first, dissolving crude cefodizime sodium salt in an acetone aqueous solution, then adding activated carbon to adsorb and filter, cooling the filtrate, stirring to separate the solid out, adding an acetone solvent to separate the solid out, filtering and drying, thus obtaining the cefodizime sodium compound solid. The prepared compound solids are fine particles, and have uniform particle size distribution and good liquidity, the crystallization technology is simple, the residual amount of organic solvent is low, and the product stability and pharmaceutical safety are effectively improved.

The invention relates to ammonium tedizolid phosphate, ammonium tedizolid phosphate crystal and their preparation method and medical use. The preparation method has simple processes and is conducive to industrial production. The ammonium tedizolid phosphate crystal A has good solubility. The preparation method has simple processes, is easy to operate, produces small pollution and can be industrialized. The ammonium tedizolid phosphate crystal drug has high purity, excellent physical and chemical properties, good chemical stability and reproducibility of processing. Compared with the tedizolid phosphate crystal, the ammonium tedizolid phosphate crystal A has good solubility, good clarity, a fast filtration rate, good hygroscopicity and good color.

Disclosed in the present invention is a preparation method of azoxystrobin having a structure as shown by formula (1), the method comprising: a) performing an etherification reaction by reacting the compound having a structure shown by formula (2) with 2-cyanophenol and / or a salt thereof under the catalysis of an azabicyclo tertiary amine compound and / or a salt thereof as the catalyst in a butyl acetate medium to obtain a butyl acetate solution containing azoxystrobin; and b) cooling the butyl acetate solution containing azoxystrobin to precipitate Azoxystrobin having a structure as shown by formula (1) from the butyl acetate solution. Using the method provided by the present invention to prepare azoxystrobin can significantly improve the yield of azoxystrobin, and can obtain azoxystrobin products having high purity.

The present invention relates to a new crystal form I of pentostatin and its preparation method and use. The crystal form I has good solubility and is conducive to improving the intestinal absorption and oral bioavailability of the drug; the crystal form I of the present invention The medicine also has the advantages of high product purity, excellent physical and chemical properties, good chemical stability, and reproducible processing (filtration, drying, and tabletting); the crystallization process of the invention is simple, easy to operate, and less polluting, and can realize industrial production.